×
ADVERTISEMENT
ADVERTISEMENT

AstraZeneca withdraws application for lung cancer drug in EU

The drug belongs to a promising class known as antibody drug conjugates (ADC), which consist of tumour-seeking monoclonal antibodies that are combined with a cell-killing chemotherapy payload.
Last Updated : 24 December 2024, 09:29 IST
ADVERTISEMENT

Follow Us :

Comments
ADVERTISEMENT
Published 24 December 2024, 09:29 IST

Follow us on :

Follow Us